The avalanche is coming... and just now it's starting to snow

Richard Aspinall, Pierre Olivier Lang

Research output: Contribution to journalArticle

5 Citations (Scopus)
6 Downloads (Pure)

Abstract

Previous vaccine development has been driven mainly by policies and concerns around childhood, with the aim of preventing premature death amongst young children from infectious disease and stopping them from acting as carriers. Whilst this is important, the face of the world has changed recently and the problem has now to be extended to include the protection of a vulnerable aging population. Here we present the case for a need to develop a prophylactic regimen for older individuals which features vaccination at the center of a portfolio of treatments. Advances in medical, social, and economic conditions have resulted in human population growth and an ever-extending life expectancy such that for the first time in our history the world population will soon have more people over the age of 65 than under the age of 5. The development of antibiotic therapy, progresses in vaccine technology combined with mass vaccination programs and government schemes to improve economic and social well-being mean that the majority of individuals over the age of 65 are currently physically more active than their counterparts a few decades ago (Michel et al., 2008). Moreover these individuals now travel more than either their parents or grandparents. The world is now so closely networked that any pathogen may spread across the globe within hours, as was observed with the recent H5N1 and H1N1 pandemics (Lang and Aspinall, 2012). In addition to the continuing trend toward increased life expectancy and the shifting demographics, the incidence and prevalence of chronic diseases are also expected to reach unprecedented levels as evidenced from a recent study on individuals over 80 years of age, which showed that many are living with an increasing number of comorbidities (Collerton et al., 2009).

Original languageEnglish
Article number65
JournalFrontiers in Immunology
Volume4
Issue numberJUN
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Avalanches
Snow
Life Expectancy
Economics
Government Programs
Mass Vaccination
Combined Vaccines
Medical Economics
Premature Mortality
Population Growth
Social Conditions
Pandemics
Vulnerable Populations
Communicable Diseases
Comorbidity
Vaccination
Chronic Disease
Vaccines
Parents
History

Bibliographical note

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The avalanche is coming... and just now it's starting to snow. / Aspinall, Richard; Lang, Pierre Olivier.

In: Frontiers in Immunology, Vol. 4, No. JUN, 65, 2013.

Research output: Contribution to journalArticle

@article{3ed1f5be02aa48eaa51a7f6e43230936,
title = "The avalanche is coming... and just now it's starting to snow",
abstract = "Previous vaccine development has been driven mainly by policies and concerns around childhood, with the aim of preventing premature death amongst young children from infectious disease and stopping them from acting as carriers. Whilst this is important, the face of the world has changed recently and the problem has now to be extended to include the protection of a vulnerable aging population. Here we present the case for a need to develop a prophylactic regimen for older individuals which features vaccination at the center of a portfolio of treatments. Advances in medical, social, and economic conditions have resulted in human population growth and an ever-extending life expectancy such that for the first time in our history the world population will soon have more people over the age of 65 than under the age of 5. The development of antibiotic therapy, progresses in vaccine technology combined with mass vaccination programs and government schemes to improve economic and social well-being mean that the majority of individuals over the age of 65 are currently physically more active than their counterparts a few decades ago (Michel et al., 2008). Moreover these individuals now travel more than either their parents or grandparents. The world is now so closely networked that any pathogen may spread across the globe within hours, as was observed with the recent H5N1 and H1N1 pandemics (Lang and Aspinall, 2012). In addition to the continuing trend toward increased life expectancy and the shifting demographics, the incidence and prevalence of chronic diseases are also expected to reach unprecedented levels as evidenced from a recent study on individuals over 80 years of age, which showed that many are living with an increasing number of comorbidities (Collerton et al., 2009).",
author = "Richard Aspinall and Lang, {Pierre Olivier}",
note = "This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.",
year = "2013",
doi = "10.3389/fimmu.2013.00165",
language = "English",
volume = "4",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media",
number = "JUN",

}

TY - JOUR

T1 - The avalanche is coming... and just now it's starting to snow

AU - Aspinall, Richard

AU - Lang, Pierre Olivier

N1 - This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

PY - 2013

Y1 - 2013

N2 - Previous vaccine development has been driven mainly by policies and concerns around childhood, with the aim of preventing premature death amongst young children from infectious disease and stopping them from acting as carriers. Whilst this is important, the face of the world has changed recently and the problem has now to be extended to include the protection of a vulnerable aging population. Here we present the case for a need to develop a prophylactic regimen for older individuals which features vaccination at the center of a portfolio of treatments. Advances in medical, social, and economic conditions have resulted in human population growth and an ever-extending life expectancy such that for the first time in our history the world population will soon have more people over the age of 65 than under the age of 5. The development of antibiotic therapy, progresses in vaccine technology combined with mass vaccination programs and government schemes to improve economic and social well-being mean that the majority of individuals over the age of 65 are currently physically more active than their counterparts a few decades ago (Michel et al., 2008). Moreover these individuals now travel more than either their parents or grandparents. The world is now so closely networked that any pathogen may spread across the globe within hours, as was observed with the recent H5N1 and H1N1 pandemics (Lang and Aspinall, 2012). In addition to the continuing trend toward increased life expectancy and the shifting demographics, the incidence and prevalence of chronic diseases are also expected to reach unprecedented levels as evidenced from a recent study on individuals over 80 years of age, which showed that many are living with an increasing number of comorbidities (Collerton et al., 2009).

AB - Previous vaccine development has been driven mainly by policies and concerns around childhood, with the aim of preventing premature death amongst young children from infectious disease and stopping them from acting as carriers. Whilst this is important, the face of the world has changed recently and the problem has now to be extended to include the protection of a vulnerable aging population. Here we present the case for a need to develop a prophylactic regimen for older individuals which features vaccination at the center of a portfolio of treatments. Advances in medical, social, and economic conditions have resulted in human population growth and an ever-extending life expectancy such that for the first time in our history the world population will soon have more people over the age of 65 than under the age of 5. The development of antibiotic therapy, progresses in vaccine technology combined with mass vaccination programs and government schemes to improve economic and social well-being mean that the majority of individuals over the age of 65 are currently physically more active than their counterparts a few decades ago (Michel et al., 2008). Moreover these individuals now travel more than either their parents or grandparents. The world is now so closely networked that any pathogen may spread across the globe within hours, as was observed with the recent H5N1 and H1N1 pandemics (Lang and Aspinall, 2012). In addition to the continuing trend toward increased life expectancy and the shifting demographics, the incidence and prevalence of chronic diseases are also expected to reach unprecedented levels as evidenced from a recent study on individuals over 80 years of age, which showed that many are living with an increasing number of comorbidities (Collerton et al., 2009).

UR - http://www.scopus.com/inward/record.url?scp=84883768731&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2013.00165

DO - 10.3389/fimmu.2013.00165

M3 - Article

VL - 4

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - JUN

M1 - 65

ER -